Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682484 | 0.91 | JAK2 (0.33) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL6256094 | 0.87 | — | — | |
| SCHEMBL5696892 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL17029138 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL5682345 | 0.86 | ALDH1A1 (0.36) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL929455 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL5680467 | 0.82 | LMNA (0.34) | ALDH1A1LMNAHSD17B10NLRP3 | |
| SCHEMBL23675572 | 0.82 | ALDH1A1 (0.36) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL31640166 | 0.81 | LMNA (0.47) | ALDH1A1LMNAJAK2JAK1TYK2 | |
| SCHEMBL20087550 | 0.79 | PKM (0.44) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1184396-B1 | (Meth)acrylate ester-based resin composition | NIPPON CATALYTIC CHEM IND (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6686413-B2 | AQUEOUS DISPERSON OF A POLYMER CONTAINING UNITS OF A CYCLOHEXYLALKYL ESTER OF (METH)ACRYLIC ACID | NIPPON SHOKUBAI CO., LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-6489396-B2 | A CYCLOHEXYL CONTAINING (METH)ACRYLIC ESTER-BASED POLYMER CROSSLINKED WITH A DI-FUNCTIONAL CROSSLINKING AGENT; LOW VISCOSITY RESIN FOR LOW VOLATILE ORGANIC COMPOUND (VOC)-PAINTS | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020091197-A1 | (Meth)acrylate ester-based resin composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-07-11 | — | — | US | disclosed |
| EP-1205498-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1184396-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | MNAT1, MAT1A, COPE | ALDH1A1 298/4885LMNA 1220/4885JAK2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.